Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Consequences of host heterogeneity, epitope immunodominance, and immune breadth for strain competition.

Cobey S, Pascual M.

J Theor Biol. 2011 Feb 7;270(1):80-7. doi: 10.1016/j.jtbi.2010.11.009. Epub 2010 Nov 18.

2.

Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.

Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR.

PLoS One. 2010 Aug 17;5(8):e12237. doi: 10.1371/journal.pone.0012237.

3.

Nonlinear least-squares data fitting in Excel spreadsheets.

Kemmer G, Keller S.

Nat Protoc. 2010 Feb;5(2):267-81. doi: 10.1038/nprot.2009.182. Epub 2010 Jan 28.

PMID:
20134427
4.

Flow cytometry-based methods for assessing soluble scFv activities and detecting antigens in solution.

Gray SA, Weigel KM, Miller KD, Ndung'u J, B├╝scher P, Tran T, Baird C, Cangelosi GA.

Biotechnol Bioeng. 2010 Apr 1;105(5):973-81. doi: 10.1002/bit.22607.

5.

Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.

Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR.

PLoS One. 2009;4(4):e5355. doi: 10.1371/journal.pone.0005355. Epub 2009 Apr 28.

6.

Yeast surface display for protein engineering and characterization.

Gai SA, Wittrup KD.

Curr Opin Struct Biol. 2007 Aug;17(4):467-73. Epub 2007 Sep 17. Review.

7.

Isolating and engineering human antibodies using yeast surface display.

Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD.

Nat Protoc. 2006;1(2):755-68.

PMID:
17406305
8.

Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.

Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD.

J Mol Biol. 2007 Jan 5;365(1):196-210. Epub 2006 Oct 3.

9.

The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples.

Kalb SR, Moura H, Boyer AE, McWilliams LG, Pirkle JL, Barr JR.

Anal Biochem. 2006 Apr 1;351(1):84-92. Epub 2006 Feb 3.

PMID:
16500606
10.

Botulinum neurotoxin detection and differentiation by mass spectrometry.

Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, Pavlopoulos A, McWilliams LG, Schmidt JG, Martinez RA, Ashley DL.

Emerg Infect Dis. 2005 Oct;11(10):1578-83.

11.

Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics.

Kalb SR, Goodnough MC, Malizio CJ, Pirkle JL, Barr JR.

Anal Chem. 2005 Oct 1;77(19):6140-6.

PMID:
16194071
12.

Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.

Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD.

J Mol Biol. 2005 Aug 5;351(1):158-69.

PMID:
16002090
13.

From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry.

Boyer AE, Moura H, Woolfitt AR, Kalb SR, McWilliams LG, Pavlopoulos A, Schmidt JG, Ashley DL, Barr JR.

Anal Chem. 2005 Jul 1;77(13):3916-24.

PMID:
15987092
14.

Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli.

Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ.

Protein Expr Purif. 2005 Aug;42(2):255-67.

PMID:
15946857
15.

High efficiency recovery and epitope-specific sorting of an scFv yeast display library.

Siegel RW, Coleman JR, Miller KD, Feldhaus MJ.

J Immunol Methods. 2004 Mar;286(1-2):141-53.

PMID:
15087229
16.

Flow cytometric screening of yeast surface display libraries.

Feldhaus M, Siegel R.

Methods Mol Biol. 2004;263:311-32.

PMID:
14976374
17.

Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library.

Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, Cochran JR, Heinzelman P, Colby D, Swers J, Graff C, Wiley HS, Wittrup KD.

Nat Biotechnol. 2003 Feb;21(2):163-70. Epub 2003 Jan 21.

PMID:
12536217
18.

Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F.

Schmidt JJ, Stafford RG.

Appl Environ Microbiol. 2003 Jan;69(1):297-303. Erratum in: Appl Environ Microbiol. 2003 May;69(5):3025.

19.

Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.

Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD.

Vaccine. 2002 Feb 22;20(11-12):1640-8.

PMID:
11858873
20.

Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.

Mullaney BP, Pallavicini MG, Marks JD.

Infect Immun. 2001 Oct;69(10):6511-4.

Supplemental Content

Support Center